Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective Multicenter Single-Arm Observational Study
Sponsor: Mayo Clinic
A observational or N/A phase clinical study on FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by Mayo Clinic and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting
-
Jul 2025 — Sep 2025 [monthly]
Recruiting
-
Feb 2025 — Jul 2025 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Jan 2025 — Feb 2025 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Essen, Germany , Houston, United States , Kefar Sava, Israel , Las Palmas, Spain , Lugano, Switzerland , Madrid, Spain , Milan, Italy , Montreal, Canada , Monza, Italy , Naples, Italy and 9 more locations